Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-9 of 9
Keywords: Dasatinib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Failure of Treatment-Free Remission after a Prolonged Deep Molecular Response in Patients with Chronic Myeloid Leukemia
Available to PurchasePatrice E. Nasnas, Elias J. Jabbour, Koji Sasaki, Ghayas C. Issa, Lucia Masarova, Nicholas J. Short, Fadi G. Haddad
Journal:
Acta Haematologica
Acta Haematol (2025) 148 (1): 105–110.
Published Online: 04 April 2024
... from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Relapse Chronic myeloid leukemia Dasatinib Imatinib Discontinuation With the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), the outcome of patients with chronic myeloid...
Journal Articles
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium
Available to PurchaseTimothy Devos, Gregor Verhoef, Eva Steel, Dominiek Mazure, Philippe Lewalle, Dominique Bron, Zwi Berneman, Fleur Samantha Benghiat, Philippe Mineur, Koen Theunissen, Pierre Zachée, Chantal Doyen, Natalie Put, Marie Lejeune, Koen Van Eygen, Violaine Havelange, Michael Reusens, Wim Pluymers, Karen Peeters
Journal:
Acta Haematologica
Acta Haematol (2019) 142 (4): 197–207.
Published Online: 04 June 2019
.../discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due...
Journal Articles
Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients
Available to PurchaseJiaqi Tan, Mengxing Xue, Jinlan Pan, Jiannong Cen, Xiaomei Qi, Ping Liu, Xiaohong Zhao, Pin Wu, Qinrong Wang, Dandan Liu, Yuejun Liu, Suning Chen, Zhi Wang
Journal:
Acta Haematologica
Acta Haematol (2019) 142 (2): 79–86.
Published Online: 16 May 2019
...Jiaqi Tan; Mengxing Xue; Jinlan Pan; Jiannong Cen; Xiaomei Qi; Ping Liu; Xiaohong Zhao; Pin Wu; Qinrong Wang; Dandan Liu; Yuejun Liu; Suning Chen; Zhi Wang We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia...
Journal Articles
Dasatinib-Induced T-Cell-Mediated Colitis: A Case Report and Review of the Literature
Available to PurchaseSubject Area:
Topic Article Package: Pharmacology 2016
, Topic Article Package: Stroke
, Hematology
, Oncology
Journal:
Acta Haematologica
Acta Haematol (2016) 136 (4): 219–228.
Published Online: 23 September 2016
...Mohamed Shanshal; Andrew Shakespeare; Seshadri Thirumala; Boyd Fenton; Donald P. Quick Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating...
Journal Articles
Beatriz Felicio Ribeiro, Bruna Rocha Vergílio, Eliana Cristina Martins Miranda, Maria Helena Almeida, Marcia Torresan Delamain, Rosana Antunes da Silveira, Carmino Antonio de Souza, Dulcinéia Martins Albuquerque, Andrey Dos Santos, Vagner Oliveira Duarte, Gislaine Borba Oliveira-Duarte, Irene Lorand-Metze, Katia Borgia Barbosa Pagnano
Journal:
Acta Haematologica
Acta Haematol (2015) 134 (4): 248–254.
Published Online: 04 July 2015
... Lorand-Metze; Katia Borgia Barbosa Pagnano Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21...
Journal Articles
Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
Available to Purchase
Journal:
Acta Haematologica
Acta Haematol (2013) 130 (4): 268–278.
Published Online: 15 August 2013
... according to 3-month BCR-ABL levels across several clinical trials [ 31,41,42,44,45,46,47 ] In a retrospective analysis of the phase III DASISION trial, achieving BCR-ABL transcript levels of ≤10% at 3 months, compared with levels of >10%, in both the dasatinib and imatinib arms, provided...
Journal Articles
Dasatinib Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation for an Isolated Central Nervous System Blast Crisis in Chronic Myelogenous Leukemia
Available to PurchaseMitsutaka Nishimoto, Hirohisa Nakamae, Ki-Ryang Koh, Saori Kosaka, Kana Matsumoto, Kunihiko Morita, Hideo Koh, Takahiko Nakane, Masahiko Ohsawa, Masayuki Hino
Journal:
Acta Haematologica
Acta Haematol (2013) 130 (2): 111–114.
Published Online: 29 March 2013
... therapy with dasatinib, intrathecal chemotherapy and cranial irradiation. Subsequently, 168 days after allogeneic HSCT, he was started on dasatinib maintenance therapy to prevent a CNS relapse. Thirty-eight months after allogeneic HSCT, he has sustained a complete molecular response in both bone marrow...
Journal Articles
Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
Available to PurchaseMariana Serpa, Israel Bendit, Fernanda Seguro, Flavia Xavier, Marcela Cavalcante, Daniel Steinbaum, Luciana Nardinelli, Vera Lucia Aldred, Henrique Moura de Paula, Pedro Enrique Dorlhiac-Llacer
Journal:
Acta Haematologica
Acta Haematol (2010) 124 (2): 105–109.
Published Online: 19 August 2010
... month of treatment. During the follow-up, his lymphocyte number doubled in <6 months. Based on previous reports, dasatinib was chosen instead of imatinib. After 6 months of treatment with 100 mg/day of dasatinib, the patient demonstrated a partial response, characterized by the regression of lymph...
Journal Articles
Pre-Emptive Treatment with Nilotinib after Second Allogeneic Transplantation in a Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patient with High Risk of Relapse
Available to Purchase
Journal:
Acta Haematologica
Acta Haematol (2010) 123 (4): 242–247.
Published Online: 12 May 2010
... have undergone prior allo-HSCT. This report presents the case of a patient with a post-transplant persistent positive BCR/ABL value, who was treated with imatinib and dasatinib before a second allo-HSCT. The patient started taking nilotinib due to a persistent BCR/ABL value and residual mass in her...